Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

NCT05435274 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-Small-Cell Lung Cancer

Interventions

DRUG: HS-10376

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.